Correlation Between Lyra Therapeutics and Reviva Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lyra Therapeutics and Reviva Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyra Therapeutics and Reviva Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lyra Therapeutics and Reviva Pharmaceuticals Holdings, you can compare the effects of market volatilities on Lyra Therapeutics and Reviva Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyra Therapeutics with a short position of Reviva Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyra Therapeutics and Reviva Pharmaceuticals.

Diversification Opportunities for Lyra Therapeutics and Reviva Pharmaceuticals

-0.37
  Correlation Coefficient

Very good diversification

The 3 months correlation between Lyra and Reviva is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding Lyra Therapeutics and Reviva Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Reviva Pharmaceuticals and Lyra Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyra Therapeutics are associated (or correlated) with Reviva Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Reviva Pharmaceuticals has no effect on the direction of Lyra Therapeutics i.e., Lyra Therapeutics and Reviva Pharmaceuticals go up and down completely randomly.

Pair Corralation between Lyra Therapeutics and Reviva Pharmaceuticals

Given the investment horizon of 90 days Lyra Therapeutics is expected to under-perform the Reviva Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Lyra Therapeutics is 2.96 times less risky than Reviva Pharmaceuticals. The stock trades about -0.05 of its potential returns per unit of risk. The Reviva Pharmaceuticals Holdings is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  18.00  in Reviva Pharmaceuticals Holdings on September 26, 2024 and sell it today you would lose (5.00) from holding Reviva Pharmaceuticals Holdings or give up 27.78% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Lyra Therapeutics  vs.  Reviva Pharmaceuticals Holding

 Performance 
       Timeline  
Lyra Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lyra Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Reviva Pharmaceuticals 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Reviva Pharmaceuticals Holdings are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady technical indicators, Reviva Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Lyra Therapeutics and Reviva Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lyra Therapeutics and Reviva Pharmaceuticals

The main advantage of trading using opposite Lyra Therapeutics and Reviva Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyra Therapeutics position performs unexpectedly, Reviva Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reviva Pharmaceuticals will offset losses from the drop in Reviva Pharmaceuticals' long position.
The idea behind Lyra Therapeutics and Reviva Pharmaceuticals Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Complementary Tools

Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Bonds Directory
Find actively traded corporate debentures issued by US companies
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
CEOs Directory
Screen CEOs from public companies around the world